Financings
Acylin Pharmaceuticals Inc. raised an undisclosed amount of Series A funding to target acetylation.
Anacor Pharmaceuticals Inc. raised $60 million in its IPO and $10 million in a private placement.
Bavarian Nordic A/S raised $36.2 million in a private placement of stock.
BG Medicine Inc. plans to sell 4.75 million shares for $13 to $15 each in its IPO, raising $67 million.
BioTheryX Inc. got an undisclosed amount of equity funding from the Leukemia & Lymphoma Society.
PharmAthene Inc. raised $14. 1 million in its previously announced public stock offering.
PhaseBio Pharmaceuticals Inc. added $15 million to its Series B financing.
Regenesance BV raised an undisclosed amount of seed funding for preclinical complement research.
SuppreMol GmbH raised $20.3 million in Series C financing.
Theravance Inc. is raising $129.3 million in a private stock placement with partner GlaxoSmithKline plc.
ThromboGenics NV is raising $46.3 million in a private placement.
Deals
Ascenta Therapeutics Inc. partnered with Ascentage Pharma Group Corp. Ltd. on two cancer drugs.
AVEO Pharmaceuticals Inc. got $25 million in an expanded discovery deal with Astellas Pharma Inc.
Axcan Holdings Inc. is acquiring Eurand NV for $583 million.
Galenica AG teamed up with Fresenius Medical Care AG & Co. KGaA on a new renal drug company.
Insmed Inc. and Transave Inc. are merging in a stock swap
SmartCells Inc. is being acquired by Merck & Co. Inc. for $500 million.
. . . And More
Amarin Corp.'s AMR101 (ethyl icosapentate) lowered triglycerides but not LDL-C in Phase III.
Basilea Pharmaceutica AG got $130 million in arbitration from ceftobiprole partner Johnson & Johnson.
Icagen Inc.'s stock jumped 78 percent when partner Pfizer Inc. selected a lead pain candidate.
Keryx Biopharmaceuticals Inc.'s Zerenex (ferric citrate) met its endpoints in a Phase III dialysis trial.
NanoBio Corp. won a $6 million grant for an intranasal respiratory syncytial virus vaccine.
Valeant Pharmaceuticals International Inc. and GlaxoSmithKline plc got a complete response letter for epilepsy drug ezogabine.